Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation
Cui W, Bai Y, Miao X, Luo P, Chen Q, Tan Y, Rane MJ, Miao L, Cai L
Oxidative medicine and cellular longevity · 103 citations
How it was studied
- Design
- Animal study (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Nonprofit
- American Diabetes Association
- University or hospital
- Wenzhou Medical College
- Grants
- Wenzhou Medical College (1-11-BA-0117); American Diabetes Association (1-11-BA-0117)
Based on 2 listed funder(s).
Publication
- Published
- 2012-01-01 · Oxid Med Cell Longev · vol. 2012 · pp. 1–12
- Publisher
- Hindawi Publishing Corporation
- Cited
- 141 citations · more than 96% of similar papers · 4.5× the field average
- Impact
- Top 10% most cited in its field
- References
- 33 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Genomics, phytochemicals, and oxidative stress · Biochemical Acid Research Studies · Chemotherapy-induced organ toxicity mitigation
- Keywords
- Sulforaphane, Diabetic nephropathy, Diabetes mellitus, Medicine, Streptozotocin, Downregulation and upregulation, Endocrinology, Nephropathy, Internal medicine, Oxidative stress, Kidney, Fibrosis, Cancer research, Chemistry, Biochemistry
- MeSH
- cell line, animals, humans, mice, diabetic nephropathies, diabetes mellitus, experimental, disease models, animal, mannitol, thiocyanates, isothiocyanates, sulfoxides, nad(p)h dehydrogenase (quinone), catalase, superoxide dismutase, glucose, palmitates, rna, small interfering, anticarcinogenic agents, rna interference, up-regulation, oxidative stress, male, nf-e2-related factor 2, heme oxygenase-1
9 authors
From US, CN
- Wenpeng CuiUniversity of Louisville; Second Affiliated Hospital of Jilin University; Baxter (United States)
- Yang BaiUniversity of Louisville; People 's Hospital of Jilin Province; Baxter (United States)
- Xiao MiaoUniversity of Louisville; Second Affiliated Hospital of Jilin University; Baxter (United States)
- Ping LuoSecond Affiliated Hospital of Jilin University
- Qiang ChenUniversity of Louisville; Jilin University; Baxter (United States)
- Yi TanUniversity of Louisville; Wenzhou Medical University; Baxter (United States)
Abstract
The present study was to investigate whether sulforaphane (SFN) can prevent diabetic nephropathy in type 1 diabetic mouse model induced by multiple low-dose streptozotocin. Diabetic and age-matched control mice were given SFN at 0.5 mg/kg body weight daily for 3 months. At the end of 3-month SFN treatment, the diabetic nephropathy, shown by renal inflammation, oxidative damage, fibrosis, and dysfunction, was significantly prevented along with an elevation of renal Nrf2 expression and transcription in diabetes/SFN group compared with diabetic group. However, this renal prevention by SFN was not seen when the 3-month SFN-treated diabetic mice were aged for additional 3 months without further SFN treatment. Nrf2-mediated renal protective effects in diabetes were evaluated in human renal tubular HK11 cells transfected with control and Nrf2 siRNA and treated with 27.5 mM mannitol or high glucose plus palmitate (300 μM). Blockade of Nrf2 expression completely abolished SFN prevention of the profibrotic effect induced by high glucose plus palmitate. These results support that renal Nrf2 expression and its transcription play important roles in SFN prevention of diabetes-induced renal damage. However, the SFN preventive effect on diabetes-induced renal pathogeneses is not sustained, suggesting the requirement of continual use of SFN for its sustained effect.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.